Novaliq in the U.S.A.

Transforming ocular therapies in the biggest healthcare market

Novaliq in the U.S.A.

Novaliq Inc. is dedicated to leverage the advantages and the potential of the first and only water-free EyeSol^® technology and its innovative products for the U.S. market. It is a 100% subsidiary of Novaliq GmbH.

The Cambridge-based office is headed by Dr. Christian Roesky, Novaliq’s President of the Novaliq Inc.

Novaliq Inc.

Harvard Square One Mifflin Place Suite 400
Cambridge, MA 02138
info.US@novaliq.com

Kartendarstellung: OpenStreetMap – Veröffentlicht unter ODbL

Betaliq Inc. is developing two beta blockers, for the treatment of glaucoma.

BTQ 1901 is an EyeSol^® based formulation of a potent selective beta blocker that has not previously been used to treat glaucoma.
BTQ 1902 is an EyeSol^® based formulation of timolol, the most commonly prescribed beta blocker.

Novaliq is a majority shareholder of Betaliq Inc. Betaliq Inc. is incorporated in Delaware and based in Tampa Florida headed by Barry Butler, an entrepreneur with 30 years of pharmaceutical experience.

Betaliq Inc.

3030 Rocky Pointe Dr., W-S 150
Tampa, FL 33607info.US@novaliq.com

Novaliq offers an industry-leading portfolio addressing today’s unmet medical needs of millions of patients with eye diseases based on its proprietary water-free eyedrop technology. On May 18th, 2023, U.S. Food and Drug Administration (FDA) approved MIEBO™ (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) followed by the approval of VEVYE™ (cyclosporine ophthalmic solution, development name CyclASol®) 0.1% on May 30th, 2023.

Both products are commercially available in the US through our partners. For prescription information see respective FDA websites.

About us

Management

Our team of seasoned industry experts explores the world of water-free therapies to develop best-in-class ocular therapies. We expand into other eye care indications and topical therapeutics spaces.